TY - JOUR T1 - The Marine-Derived Oligosaccharide Sulfate MS80, a Novel Transforming Growth Factor <em>β</em>1 Inhibitor, Reverses Epithelial Mesenchymal Transition Induced by Transforming Growth Factor-<em>β</em>1 and Suppresses Tumor Metastasis JF - Journal of Pharmacology and Experimental Therapeutics JO - J Pharmacol Exp Ther SP - 54 LP - 61 DO - 10.1124/jpet.116.234799 VL - 359 IS - 1 AU - Ji Zhou AU - Wenjie You AU - Guangqiang Sun AU - Yixuan Li AU - Bi Chen AU - Jing Ai AU - Handong Jiang Y1 - 2016/10/01 UR - http://jpet.aspetjournals.org/content/359/1/54.abstract N2 - Metastasis accounts for the majority of cancer-related deaths. Transforming growth factor β (TGF-β) is believed to promote late-stage cancer progression and metastasis by inducing epithelial-mesenchymal transition (EMT). We previously reported that MS80, a novel oligosaccharide sulfate, inhibits TGF-β1–induced pulmonary fibrosis by binding TGF-β1. In our study MS80 effectively inhibited TGF-β/Smad signaling in lung cancer cells, breast cancer cells, and model cell lines. In addition, MS80 inhibited TGF-β1–induced EMT, motility, and invasion in vitro. Moreover, MS80 significantly inhibited lung metastasis in orthotopic 4T1 xenografts. Notably, the MS80 treatment significantly increased the infiltration of CD8+ T cells and decreased the infiltration of regulatory T cells in primary tumors and spleens in mice bearing 4T1 xenografts. Therefore, MS80 is a novel and promising candidate for treating metastatic malignancies by targeting TGF-β1–induced EMT and mediating immunosuppression. ER -